Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found in connective, epithelial, and neural tissues. Therapeutic formulations include intra-articular injections (viscosupplementation) and topical/ophthalmic preparations. Therapeutic effects are mediated by lubrication, shock absorption, and moisture retention.
## Primary Indications
* **Intra-articular:** Osteoarthritis (OA) of the knee (when conservative therapy fails).
* **Topical:** Skin hydration, wound healing, and dermatitis.
* **Ophthalmic:** Dry eye syndrome.
## Adult Dosing
* **Osteoarthritis (Intra-articular):**
* *Sodium Hyaluronate (e.g., Euflexxa, Hyalgan, Orthovisc):* 2 mL (10-20 mg) via intra-articular injection into the affected knee.
* *Frequency:* Usually once weekly for 3 to 5 weeks depending on the specific product.
* *Maximum:* Repeat courses should not occur sooner than 6 months post-injection.
* **Ophthalmic:** 0.1%–0.3% solution applied to the affected eye(s) 3–4 times daily as needed.
## Pediatric Dosing
Safety and efficacy have not been established for intra-articular use in patients <18 years. Topical and ophthalmic use may be used off-label, but consult local institutional guidelines for age-appropriate concentrations and frequencies.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific dosage adjustments established; systemic absorption from local/intra-articular administration is negligible.
* **Weight-based:** Intra-articular doses are fixed by joint volume, not body weight.
## Contraindications
* Known hypersensitivity to hyaluronan or avian-derived proteins (for avian-sourced products).
* Active joint infection or severe inflammation in the target joint.
* Pre-existing skin infections in the injection area.
## Adverse Effects
* **Intra-articular:** Transient injection site pain, joint swelling, effusion, or stiffness. Rare: Pseudoseptic arthritis or systemic hypersensitivity.
* **Ophthalmic:** Transient blurred vision, ocular irritation/stinging.
* **Topical:** Generally well-tolerated; rare contact dermatitis.
## Key Drug Interactions
No clinically significant systemic drug-drug interactions. Avoid concurrent intra-articular injection of disinfectants containing quaternary ammonium salts (e.g., benzalkonium chloride) as they may precipitate HA.
## Monitoring
* **Clinical:** Monitor for signs of localized infection (erythema, warmth, fever) post-injection.
* **Efficacy:** Reduction in pain scores and improvement in joint mobility.
## Clinical Pearls
* **Product Sourcing:** Some products are derived from avian sources (rooster combs) and may pose a risk to patients with severe egg/poultry allergies; investigate manufacturer-specific sourcing.
* **Injection Technique:** Strict aseptic technique is critical to prevent iatrogenic septic arthritis.
* **Efficacy:** Evidence for viscosupplementation in knee OA remains controversial; clinical benefit may be modest and is highly patient-dependent.
* **Storage:** Most intra-articular products require storage at room temperature or refrigeration; do not freeze.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify prescribing information, contraindications, and specific product instructions via manufacturer package inserts or clinical resources (e.g., Lexicomp, UpToDate) before administering medication. Individual patient factors must be considered by the prescribing clinician.
